Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (571-580 of 704) with videos related to

Pageof 71
Sort By:
Nature Medicine|May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practiceClaus Garbe, Reinhard Dummer, Teresa Amaral, et al.
Nature Communications|February 19, 2021
Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2020
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic MelanomaAilin Lepletier, Jason Madore, Jake S O'Donnell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
JAMA Surgery|February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaIrene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
Genome Medicine|May 11, 2021
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysisSunny Z Wu, Daniel L Roden, Ghamdan Al-Eryani, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaEleanor E Handel, Janet McKeown, Joe Wei, et al.
JAMA Network Open|February 16, 2024
Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in EuropeLara V Maul, Dagmar Jamiolkowski, Rebecca A Lapides, et al.
Pageof 71

Showing results (571-580 of 704) with videos related to

Sort By:
Pageof 71
Nature Medicine|May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practiceClaus Garbe, Reinhard Dummer, Teresa Amaral, et al.
Nature Communications|February 19, 2021
Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2020
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic MelanomaAilin Lepletier, Jason Madore, Jake S O'Donnell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
JAMA Surgery|February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaIrene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
Genome Medicine|May 11, 2021
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysisSunny Z Wu, Daniel L Roden, Ghamdan Al-Eryani, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaEleanor E Handel, Janet McKeown, Joe Wei, et al.
JAMA Network Open|February 16, 2024
Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in EuropeLara V Maul, Dagmar Jamiolkowski, Rebecca A Lapides, et al.
Pageof 71